ALX Oncology Holdings Inc.

74.98-3.80-4.82%Vol 75.63K1Y Perf 92.38%
Sep 24th, 2021 16:00 DELAYED
BID74.98 ASK75.26
Open77.85 Previous Close78.78
Pre-Market- After-Market-
 - -  - -%
Target Price
97.00 
Analyst Rating
— — 0.00
Potential %
29.37 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
★★★★+     60.09
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Price Range Ratio 52W %
50.00 
Earnings Rating
Market Cap3.02B 
Earnings Date
11th Nov 2021
Alpha-0.04 Standard Deviation0.28
Beta4.88 

Today's Price Range

74.9679.00

52W Range

32.51117.45

Summary:

Neutral

Technical Indicators: Neutral
Moving Averages: Buy
Performance
1 Week
-3.64%
1 Month
1.21%
3 Months
30.99%
6 Months
10.66%
1 Year
92.38%
3 Years
-
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
ALXO74.98-3.8000-4.82
AAPL146.920.09000.06
GOOG2 852.6616.13000.57
MSFT299.35-0.2100-0.07
XOM57.590.51000.89
WFC47.920.12000.25
JNJ164.36-0.5000-0.30
FB352.967.00002.02
GE103.800.84000.82
JPM163.041.86001.15
Earnings HistoryEstimateReportedSurprise %
Q02 2021-0.48-0.4016.67
Q01 2021-0.50-0.3530.00
Q04 2020-0.36-0.48-33.33
Q03 2020-0.37-0.355.41
Q02 2020-0.29-4.28-1 375.86
----
----
----
Earnings Per EndEstimateRevision %Trend
----
----
----
----
Next Report Date11th Nov 2021
Estimated EPS Next Report-0.46
Estimates Count3
EPS Growth Next 5 Years %-
Volume Overview
Volume75.63K
Shares Outstanding40.34M
Shares Float17.48M
Trades Count2.06K
Dollar Volume23.72M
Avg. Volume244.46K
Avg. Weekly Volume136.08K
Avg. Monthly Volume200.77K
Avg. Quarterly Volume291.77K

ALX Oncology Holdings Inc. (NASDAQ: ALXO) stock closed at 74.98 per share at the end of the most recent trading day (a -4.82% change compared to the prior day closing price) with a volume of 75.63K shares and market capitalization of 3.02B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 15 people. ALX Oncology Holdings Inc. CEO is Jaume Pons.

The one-year performance of ALX Oncology Holdings Inc. stock is 92.38%, while year-to-date (YTD) performance is -13.02%. ALXO stock has a five-year performance of %. Its 52-week range is between 32.51 and 117.45, which gives ALXO stock a 52-week price range ratio of 50.00%

ALX Oncology Holdings Inc. currently has a PE ratio of -64.80, a price-to-book (PB) ratio of 7.75, a price-to-sale (PS) ratio of 4 072.61, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -22.88%, a ROC of -37.02% and a ROE of -37.42%. The company’s profit margin is -%, its EBITDA margin is -10 159.60%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.

Of the last four earnings reports from ALX Oncology Holdings Inc., there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-0.46 for the next earnings report. ALX Oncology Holdings Inc.’s next earnings report date is 11th Nov 2021.

The consensus rating of Wall Street analysts for ALX Oncology Holdings Inc. is (), with a target price of $, which is 0.00% compared to the current price. The earnings rating for ALX Oncology Holdings Inc. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

ALX Oncology Holdings Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

ALX Oncology Holdings Inc. has a Neutral technical analysis rating based on Technical Indicators (ADX : 11.80, ATR14 : 3.66, CCI20 : 24.36, Chaikin Money Flow : -0.12, MACD : 2.47, Money Flow Index : 51.22, ROC : 1.45, RSI : 52.54, STOCH (14,3) : 35.85, STOCH RSI : 0.00, UO : 54.91, Williams %R : -64.15), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of ALX Oncology Holdings Inc. in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
0
0
0
Moderate Buy
0
0
0
Hold
0
0
0
Moderate Sell
0
0
0
Strong Sell
0
0
0
Summary Rating---

ALX Oncology Holdings Inc.

ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company. The firm is focused on developing therapies that block the CD47 checkpoint pathway and bridge the innate and adaptive immune system.

CEO: Jaume Pons

Telephone: +1 650 466-7125

Address: 866 Malcolm Road, Burlingame 94010, CA, US

Number of employees: 15

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

100%0%

Bearish Bullish

65%35%

Bearish Bullish

75%25%

News

Stocktwits